Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer

TY - JOUR

T1 - Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer

AU - Denis, Fabrice

AU - Basch, Ethan

AU - Septans, Anne Lise

AU - Bennouna, Jaafar

AU - Urban, Thierry

AU - Dueck, Amylou C.

AU - Letellier, Christophe

N1 - Funding Information: Conflict of Interest Disclosures: Dr Denis reported receiving personal fees from AstraZeneca, Ipsen, SIVAN Innovation, Pfizer, Chugai, and Roche. Dr Basch reported receiving research funding from the National Cancer Institute and Patient-Centered Outcomes Research Institute and personal fees (ie, payment for serving on the scientific advisory board) from the Centers for Medicare & Medicaid Services, SIVAN Innovation, and Noona. Dr Bennouna reported receiving personal fees from Lilly and Merck Sharp & Dohme. Dr Urban reported receiving personal fees from AstraZeneca and Novartis. No other disclosures were reported. Funding Information: Funding/Support: This study was supported by SIVAN Innovation.

PY - 2019/1/22

Y1 - 2019/1/22

UR - https://www.scopus.com/pages/publications/85060233746

UR - https://www.scopus.com/pages/publications/85060233746#tab=citedBy

U2 - 10.1001/jama.2018.18085

DO - 10.1001/jama.2018.18085

M3 - Letter

C2 - 30667494

AN - SCOPUS:85060233746

SN - 0098-7484

VL - 321

SP - 306

EP - 307

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

IS - 3

ER -